Amino.Desk

Cerebrolysin

Updated Nov 17, 2026 · Clinical review: pending

Cerebrolysin is a mixture of peptides made from pig brain tissue. More than 50 countries have approved it for stroke and dementia. The US has not, and the independent reviews that pooled its trials did not find a convincing benefit.

What it is

A preparation derived from pig brain, first described in Austria in 1949 and made by an Austrian company. It is used in parts of Europe, Asia and Latin America for stroke, traumatic brain injury and dementia. Nootropic users import it for memory and brain recovery.

What the evidence shows

This is one of the most thoroughly reviewed products in this library. Its wide use abroad does not reflect strong evidence that the FDA overlooked.

Legal status

Reported dosing

We do not publish a protocol for this compound.

Countries that approve it have their own labels, which we have not checked directly. It is given by infusion or injection under medical supervision.

Safety

Common questions

Is Cerebrolysin FDA-approved?

No. It is approved in more than 50 other countries.

Does Cerebrolysin work for stroke?

The 2023 Cochrane review of 7 trials and 1,773 patients found no benefit on death and more serious adverse events.

Is Cerebrolysin a peptide?

It is a mixture of peptides and amino acids made from pig brain, not a single defined peptide.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy